| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Outline of Final Research Achievements |
Abnormalities in the hypothalamic-pituitary-adrenal (HPA)-axis have been thought to induce refractory depression. Glucagon-like peptide-2 (GLP-2) exhibited antidepressant-like effects in ACTH-treated imipramine-resistant depression model mice through an inhibition on the release of CRH from the PVN in the hypothalamus and the restoration of neurogenesis in the SGZ of the hippocampal dentate gyrus. Intranasal administration of the newly synthesized GLP-2 derivative also showed antidepressant-like effects in ACTH-treated mice, indicating a possible clinical treatment for major depression. Furthermore, we showed memory improving effects and anxiolytic effects of GLP-2 in mice, as well as the hypotensive effects in hypertension model rats.
|
